With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman SachsBenzinga • 07/12/24
Pfizer says it has identified and selected a preferred formulation for its one-a-day obesity pillMarket Watch • 07/11/24
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist DanuglipronBusiness Wire • 07/11/24
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & DevelopmentBusiness Wire • 07/09/24
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 07/08/24